A news story examines the fate of using surrogate biomarkers in clinical trials. So far, reliance on markers that don't necessarily correlate with a disease itself has helped "fast-track" many drugs through the FDA approval process. Surprising findings about drugs, like GSK's Avandia, have people questioning dependence on these kinds of markers.